Poland· PL-100515176
Nimesil
A nimesulide product containing nimesulidum, registered in Poland by InPharm Sp. z o.o.. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Nimesulide is registered in 5 of 19 countries.
Countries holding a registration under ATC M01AX17 (nimesulide), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Nimesulide · ATC M01AX17
5 / 19 countries
- Czechiaprice
- Finlandprice
- Italyprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of nimesulide costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.18 in Italy to $4.01 in Switzerland — a ×22 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nimesulide · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$4.01
- IT Italy$0.18
The record
At a glance
URPL (Poland)- Active substance
- Nimesulidum
- Manufacturer
- InPharm Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- M01AX17
- ATC class
- Nimesulide
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909991567651
- gtin05909991567668
- gtin05909991567675
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
75 interactions on record for nimesulide.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nimesulide · interactions on record
75 records
75 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Nimesulide in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- ItalyNIMESULIDE ALMUSALMUS S.R.L.
- CzechiaAULINHelsinn Birex Pharmaceuticals Ltd., Dublin
- SwitzerlandAulin 100
- FinlandNimedHelsinn Birex Pharmaceuticals Ltd
Authorised across Europe · EMA
The same active substance is authorised in 13 EEA countries. Names it is sold under:
- Bulgaria · Aулин, Аулин
- Cyprus · Aponil, Elinap
- Czechia · Aulin, Coxtral
- Greece · Cliovyl, Dolostop
- Croatia · Dilmin
- Hungary · Mesulid, Nidol
- Italy · Actalide, Algolider
- Lithuania · Aponil, Nimesil
- Latvia · Aponil, Nimesil
- Malta · Remov
- Portugal · Aulin, Dolorilgel
- Romania · Aulin, Lemesil
- Slovakia · Aulin, Nimesil
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9fb9bd83-da2e-42c9-a729-2f86881cdec5 GET /v1/drugs/9fb9bd83-da2e-42c9-a729-2f86881cdec5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Granulat do sporządzania zawiesiny doustnej",
"source": "urpl",
"strength": "100 mg",
"packaging": "05909991567651 ¦ Rp ¦ 160991\n9 sasz. po 2 g\n05909991567668 ¦ Rp ¦ 160992\n15 sasz. po 2 g\n05909991567675 ¦ Rp ¦ 160993\n30 sasz. po 2 g",
"substance": "Nimesulidum 100 mg",
"common_name": "Nimesulidum",
"pl_product_id": "100515176",
"pozwolenie_nr": "094/25",
"auth_procedure": "IR",
"authorisation_validity": "2030-03-13"
}See everything about nimesulide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.